CytoSorbents reports Q1 adjusted EPS (5c) vs. (6c) last year

Reports Q1 revenue $8.9M vs. $8.7M last year. “First quarter sales were $8.9 million, driven by 13% growth in our direct sales territories outside of Germany,” stated Dr. Phillip Chan, Chief Executive Officer of CytoSorbents (CTSO) Corporation. “Our Germany sales team also performed well, achieving sales slightly below last year, but with a smaller and more focused team – reflecting new leadership, sales execution, account targeting, productivity, and customer engagement. Given the importance of the German market, we plan to selectively expand our commercial team to improve account coverage and drive growth opportunities in both critical care and cardiac surgery.”